替奈普酶与阿替普酶治疗急性卒中:死亡与出血并发症比较
该研究基于美国TriNetX数据库54家学术医疗中心/医疗保健组织的回顾性队列,纳入2012年1月1日后接受替奈普酶的3432例和接受阿替普酶的55894例卒中患者,经倾向评分匹配后共6864例。结果显示,替奈普酶组30天死亡率显著低于阿替普酶组(8.2% vs 9.8%;RR 0.832),输血频率也更低(0.3% vs 1.4%;RR 0.207),而颅内出血发生率无统计学差异(3.5% vs 3.0%;RR 1.185)。2021至2022年子组分析中替奈普酶组生存更好且颅内出血率更低。作者认为,结合既往随机对照试验数据及给药便捷、成本效益等优势,支持优先使用替奈普酶。
要点
- 替奈普酶组30天死亡率8.2%,阿替普酶组9.8%,RR 0.832。
- 替奈普酶组输血频率0.3%,阿替普酶组1.4%,RR 0.207,提示大出血更少。
- 10年数据集颅内出血发生率替奈普酶组3.5% vs 阿替普酶组3.0%,RR 1.185,无统计学差异。
- 2021–2022年子组匹配2216例,替奈普酶组生存更好且颅内出血率更低。
- 作者认为,结合既往RCT数据及给药便捷、成本效益,支持优先使用替奈普酶。
适用人群与场景
- 2012年1月1日后因卒中接受替奈普酶或阿替普酶治疗的患者,来源于美国TriNetX数据库54家学术医疗中心/医疗保健组织。
- 倾向评分匹配基于基本人口学信息和7个既往临床诊断组,匹配后共6864例急性卒中患者,两组各半。
- 2021至2022年子组分析纳入2216例匹配患者。
研究设计与关键结果
- 研究类型:基于美国TriNetX数据库的回顾性研究,涉及54家学术医疗中心/医疗保健组织;替奈普酶组3432例,阿替普酶组55894例,倾向评分匹配后共6864例。
- 30天死亡率:替奈普酶组8.2% vs 阿替普酶组9.8%,RR 0.832。
- 30天输血频率:替奈普酶组0.3% vs 阿替普酶组1.4%,RR 0.207。
- 30天颅内出血发生率:替奈普酶组3.5% vs 阿替普酶组3.0%,RR 1.185,无统计学差异。
- 2021至2022年子组分析(2216例匹配患者):替奈普酶组生存更好且颅内出血率更低。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,替奈普酶在急性缺血性卒中患者中显示更低死亡率、更少颅内出血和更少显著失血。
- 作者认为,结合既往随机对照试验数据及快速给药和成本效益等操作优势,支持优先使用替奈普酶。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: Intravenous thrombolysis with alteplase has been the foundation of initial treatment of acute ischemic stroke for several decades. Tenecteplase is a thrombolytic agent that offers logistical advantages in cost and administration relative to alteplase. There is evidence that tenecteplase has at least similar efficacy and safety outcomes compared with alteplase for stroke. In this study, we compared tenecteplase versus alteplase for acute stroke in a large retrospective US database (TriNetX) regarding the following 3 outcomes: (1) mortality, (2) intracranial hemorrhage, and (3) the need for acute blood transfusions.
METHODS: In this retrospective study using the US cohort of 54 academic medical centers/health care organizations in the TriNetX database, we identified 3,432 patients treated with tenecteplase and 55,894 patients treated with alteplase for stroke after January 1, 2012. Propensity score matching was performed on basic demographic information and 7 previous clinical diagnostic groups, resulting in a total of 6,864 patients with acute stroke evenly matched between groups. Mortality rates, the frequency of intracranial hemorrhage, and blood transfusions (as a marker of significant blood loss) were recorded for each group over the ensuing 7- and 30-day periods. Secondary subgroup analyses were conducted on a cohort treated from 2021 to 2022 in an attempt to determine whether temporal differences in acute ischemic stroke treatment would alter the results.
RESULTS: Patients treated with tenecteplase had a significantly lower mortality rate (8.2% versus 9.8%; risk ratio [RR], 0.832) and lower risk of major bleeding as measured by the frequency of blood transfusions (0.3% versus 1.4%; RR, 0.207) than alteplase at 30 days after thrombolysis for stroke. In the larger 10-year data set of patients with stroke treated after January 1, 2012, patients receiving tenecteplase were not found to have a statistically different incidence of intracranial hemorrhage (3.5% versus 3.0%; RR, 1.185) at 30 days after the administration of the thrombolytic agents in patients. However, a subgroup analysis of 2,216 evenly matched patients with stroke treated from 2021 to 2022 demonstrated notably better survival and statistically lower rates of intracranial hemorrhage than the alteplase group.
CONCLUSION: In our large retrospective multicenter study using real-world evidence from large health care organizations, tenecteplase for the treatment of acute stroke demonstrated a lower mortality rate, decreased intracranial hemorrhage, and less significant blood loss. The favorable mortality and safety profiles observed in this large study, taken together with previous randomized controlled trial data and operational advantages in rapid dosing and cost-effectiveness, all support the preferential use of tenecteplase in patients with ischemic stroke.
参考来源
- Murphy LR, Hill TP, Paul K, et al. Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications. Ann Emerg Med. 2023. PMID: 37178103. doi:10.1016/j.annemergmed.2023.03.022
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。